Body mass influences IOP

Article

The body mass index (BMI) of a patient may affect the results of a water-drinking test (WDT), according to study results published in October issue of the Journal of Ocular Pharmacology and Therapeutics.

The body mass index (BMI) of a patient affects intraocular pressure (IOP) readings, according to study results published in October issue of the Journal of Ocular Pharmacology and Therapeutics.

Verônica C. Lima of the department of ophthalmology at the Federal University of São Paulo, Brazil and colleagues measured the height and weight of primary open angle glaucoma (POAG) patients (n=41) and conducted the water-drinking test (WDT), evaluating IOP at four 15-minute intervals.

Dr Lima and colleagues found that patients with higher BMIs demonstrated lower peak IOP measurements when compared with lower BMI patients; the higher BMI patients also had smaller fluctuations in IOP measurements than lower BMI subjects. These differences, which related to both absolute and percentage variations, were statistically significant.

Thus the team concluded that BMI impacts WDT results to the extent that higher BMI produces lower peak IOP and reduced fluctuations in IOP levels.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.